TCM
NTLA icon

Tygh Capital Management’s Intellia Therapeutics NTLA Stock Holding History

Tygh Capital Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		$3.73M Sell
31,588
-63
-0.2% -$7.89K 0.48% 71
2021
Q3 		$4.25M Buy
+31,651
New +$4.79M 0.57% 72

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Tygh Capital Management's NTLA Position: Q4 2021 in Review

Tygh Capital Management reduced its Intellia Therapeutics (NTLA) stake by 0.2% in Q4 2021, selling an estimated $7.89K and leaving 31,588 shares worth $3.73M. The position accounts for 0.48% of the portfolio, ranked #71.

Tygh Capital Management first reported a position in NTLA in Q3 2021 and has held it in 2 quarters since. The position peaked at $4.25M in Q3 2021. 372 funds tracked by Wall St. Rank hold NTLA as of Q4 2021.

  • Tygh Capital Management held 31,588 shares of Intellia Therapeutics worth $3.73M as of Q4 2021.
  • Tygh Capital Management sold 63 Intellia Therapeutics shares in Q4 2021, an estimated $7.89K.
  • Intellia Therapeutics made up 0.48% of Tygh Capital Management's portfolio in Q4 2021, its #71 holding.
  • Tygh Capital Management first reported a position in Intellia Therapeutics in Q3 2021 and has held it in 2 quarters since.
  • Tygh Capital Management's Intellia Therapeutics position peaked at $4.25M in Q3 2021.
  • 372 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q4 2021.

Based on Tygh Capital Management's 13F filing for Q4 2021, filed 10 Feb 2022.